JP2023532732A5 - - Google Patents

Info

Publication number
JP2023532732A5
JP2023532732A5 JP2022581569A JP2022581569A JP2023532732A5 JP 2023532732 A5 JP2023532732 A5 JP 2023532732A5 JP 2022581569 A JP2022581569 A JP 2022581569A JP 2022581569 A JP2022581569 A JP 2022581569A JP 2023532732 A5 JP2023532732 A5 JP 2023532732A5
Authority
JP
Japan
Prior art keywords
drug
enpp1
enpp3
polypeptide
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040356 external-priority patent/WO2022006545A2/en
Publication of JP2023532732A publication Critical patent/JP2023532732A/ja
Publication of JP2023532732A5 publication Critical patent/JP2023532732A5/ja
Pending legal-status Critical Current

Links

JP2022581569A 2020-07-02 2021-07-02 同種移植片血管障害、モヤモヤ病、モヤモヤ症候群、及び内膜増殖を治療するための組成物及び方法 Pending JP2023532732A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063047877P 2020-07-02 2020-07-02
US202063047865P 2020-07-02 2020-07-02
US202063047793P 2020-07-02 2020-07-02
US202063047848P 2020-07-02 2020-07-02
US63/047,877 2020-07-02
US63/047,793 2020-07-02
US63/047,848 2020-07-02
US63/047,865 2020-07-02
PCT/US2021/040356 WO2022006545A2 (en) 2020-07-02 2021-07-02 Compositions and methods for treating allograft vasculopathy, moyamoya disease, moyamoya syndrome and intimal proliferation

Publications (2)

Publication Number Publication Date
JP2023532732A JP2023532732A (ja) 2023-07-31
JP2023532732A5 true JP2023532732A5 (https=) 2024-07-09

Family

ID=79317840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581569A Pending JP2023532732A (ja) 2020-07-02 2021-07-02 同種移植片血管障害、モヤモヤ病、モヤモヤ症候群、及び内膜増殖を治療するための組成物及び方法

Country Status (13)

Country Link
US (1) US20240016951A1 (https=)
EP (1) EP4175657A4 (https=)
JP (1) JP2023532732A (https=)
KR (1) KR20230048020A (https=)
CN (1) CN116322742A (https=)
AU (1) AU2021300261A1 (https=)
BR (1) BR112022026907A2 (https=)
CA (1) CA3184349A1 (https=)
CO (1) CO2023000754A2 (https=)
IL (1) IL299503A (https=)
MX (1) MX2023000247A (https=)
TW (1) TW202216186A (https=)
WO (1) WO2022006545A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549738A (ja) 2020-10-30 2023-11-29 1シーバイオ, インコーポレイテッド エクトヌクレオチドピロホスファターゼ-ホスホジエステラーゼ-1(enpp1)阻害物質及びそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846603B2 (en) * 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP3377105A4 (en) * 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
EA201991556A1 (ru) * 2016-12-22 2020-01-23 Мавуфарма, Инк. Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции

Similar Documents

Publication Publication Date Title
AU2007342674B2 (en) Polypeptide inhibitors of HSP27 kinase and uses therefor
Iwatsuki et al. Current status of hepatic transplantation
JP2024543209A5 (https=)
JP2023532732A5 (https=)
US20090275732A1 (en) Agent for improving circulatory disorder
Serrano et al. Familial mediterranean fever and acute myocardial infarction secondary to coronary vasculitis
JP2024544057A5 (https=)
JP2007508823A (ja) 新規な熱ショックタンパク質20関連ポリペプチドおよびその使用
JP2023527365A5 (https=)
Lee et al. ABO-incompatible living donor liver transplantation with a simplified desensitization and immunosuppression protocol: a single-center retrospective study
Yasuda et al. The changes in treatment strategies in ABOi living donor liver transplantation for acute liver failure
JP2995860B2 (ja) 新規ペプチド
WO2016162369A1 (fr) Nouvelle utilisation du facteur von willebrand
US20100172909A1 (en) Cerebral edema suppressant
Hällgren et al. Deposition of eosinophil cationic protein in vascular lesions in temporal arteritis.
JP2023527364A5 (https=)
CN102574905A (zh) HLA-Gα1多聚体及其药学用途
JPH10194986A (ja) 移植肝機能改善・再生促進剤
KR101351121B1 (ko) Il-27을 유효성분으로 포함하는 면역거부질환의 예방 또는 치료용 조성물
WO2001087324A1 (en) Compositions and methods for promoting immunosuppression
JP2025500508A5 (https=)
RU2024109125A (ru) Применение моноклональных антител против cd6 для предотвращения повреждений клеток и органов в результате гипервоспалительной реакции
CN115887620A (zh) Csf1-cd47在制备移植早期免疫排斥抑制剂中的应用
WO1994028932A1 (en) Immunoglobulin infusion in xenotransplantation
US20080255047A1 (en) Method of Treating Acute Renal Failure with Thrombomobulin Variant